4. Evaluate tum or infiltrating lymphocytes (TIL) by Immunohistochemistry (IHC) on pre - surgical and surgical samples. HPV immunotherapy prior to surgery will provide us with a unique opportunity to determine if the VGX-3100 induced immune response can directly target the HPV positive tumor cells . Therefore, we will perform immunohistochemistry on 27 Date: 8 April 2016 v 2.1 INO-3112 UPCC # 39313 / Inovio HPV -005 Inovio Pharmaceuticals, Inc Clinical Protocol samples obtained prior to or at study entry as well as on samples that will be obtained from resection of the primary tumor in Cohort I. 5. Evaluate phenotypes of cultured TILs. In addition, for Cohort I we will use any remaining fresh (unfixed) tissue 1) isolate TILs and 2) isolate tumor cells to use for in vitro stimulation of lymphocytes isolated from the periphery. In order to determine if HPV E6 and E7 specific lymphocytes hav e migrated to the tumor we will isolate TIL s by standard procedures from tumor pre - and post -immunotherapy . We will utilize Affymetrix/Panomics Luminex Plex System to define the immunological transcriptome. This gene analysis will incorporate analysis of P erforin, IFN -gamma, IL -2, IL -10 and IL -4 to account for antigen specific CD8 and CD4 T cells as well as Treg upregulation. In addition, confirmatory genes will be included. Such genes are transcription factors for these cell types; Tbet, GATA2, FOXP2 and RORC. Secondly, during digestion of the tumor with collagenase for lymphocytes we will save and cryopreserve tumor cells as well. These tumor cells can be used in in vitro assays to stimulate lymphocytes isolated from the periphery of the respective subject. We expect that we will observe an immune response to peptides. However, stimulation with tumor cells will provide information about lymphocytes ability to target the tumor cells. 3.2.3 Exploratory Endpoints : Clinical response criteria as determined by: 1. Any evidence of anti- tumor response as assessed by the Investigator 2. Progression f ree survival 4 Subject Selection and Withdrawal Exceptions to eligibility will not be granted for this study. 4.1 Inclusion Criteria 1. Signed and dated writte n Ethics Committee appr oved informed consent. 2. Age ≥18 years.